Expansion of endogenous T cells in CSF of pediatric and young adult CNS tumor patients undergoing locoregional delivery of IL13R⍺2-targeting CAR T cells: an interim analysis
Single-cell RNA-seq · human · 37 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart. Read from the summary: GEO's own type field only says 'expression profiling by sequencing', so confirm it in the paper.
- Organism
- Homo sapiens (human)
- Samples
- 37 samples: 37 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE261235_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1086140 and SRA study SRP494334. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 37 sample titles: 37 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8138369 CSF, UPN-514, Cycle 11 Day 1, F04857-GEX_F04902-CAR
- GSM8138370 CSF, UPN-514, Cycle 11 Day 1, F04857-GEX_F05038-TCR
- GSM8138371 CSF, UPN-515, Cycle 4 Day 2, F04858-GEX_F04903-CAR
- GSM8138372 CSF, UPN-515, Cycle 4 Day 2, F04858-GEX_F05039-TCR
- GSM8138373 CSF, UPN-574, Cycle 8 Day 1, F04859-GEX_F04904-CAR
- GSM8138374 CSF, UPN-574, Cycle 8 Day 1, F04859-GEX_F05040-TCR
- GSM8138375 CSF, UPN-514, Cycle 8 Day 1, F04862-GEX_F04906-CAR
- GSM8138376 CSF, UPN-514, Cycle 8 Day 1, F04862-GEX_F05042-TCR
- GSM8138377 CSF, UPN-515, Cycle 8 Day 1, F04863-GEX_F04907-CAR
- GSM8138378 CSF, UPN-515, Cycle 8 Day 1, F04863-GEX_F05043-TCR
- GSM8138379 CSF, UPN-574, Cycle 3, Day 1, F04864-GEX_F04908-CAR
- GSM8138380 CSF, UPN-574, Cycle 3, Day 1, F04864-GEX_F05044-TCR
- GSM8138381 CSF, UPN-514, Cycle 5 Day 1, F04865-GEX_F04884-CAR
- GSM8138382 CSF, UPN-514, Cycle 5 Day 1, F04865-GEX_F05045-TCR
- GSM8138383 CSF, UPN-515, Cycle 4 Day 2, F04866-GEX_F04899-CAR
- GSM8138384 CSF, UPN-515, Cycle 4 Day 2, F04866-GEX_F05047-TCR
- GSM8138385 CSF, UPN-514, Cycle 11 Day 1, F04867-GEX_F04898-CAR
- GSM8138386 CSF, UPN-514, Cycle 11 Day 1, F04867-GEX_F05046-TCR
- GSM8138387 CSF, UPN-574, Cycle 8 Day 1, F04868-GEX_F04900-CAR
- GSM8138388 CSF, UPN-574, Cycle 8 Day 1, F04868-GEX_F05048-TCR
- GSM8138389 Mixed, F04855-GEX_F04856-FB
- GSM8138390 Mixed, F04855-GEX_F05037-TCR
- GSM8138391 Mixed, F04860-GEX_F04861-FB
- GSM8138392 Mixed, F04860-GEX_F05041-TCR
- GSM8138393 Mixed, F05555-GEX_F05578-FB
- GSM8138394 Mixed, F05555-GEX_F05625-TCR
- GSM8138395 Tumor, UPN-574, Post-treatment, Tumor_Cells_CD45_negative, F05561-GEX_F05581-CAR
- GSM8138396 Tumor, UPN-574, Post-treatment, Tumor_Cells_CD45_positive, F05560-GEX_F05580-CAR
- GSM8138397 Tumor, UPN-574, Post-treatment, Tumor_Cells_CD45_positive, F05560-GEX_F05627-TCR
- GSM8138398 Mixed, F05554-GEX_F05583-FB
- GSM8138399 Mixed, F05554-GEX_F05626-TCR
- GSM8138400 Tumor, UPN-625, Pre-treatment, Tumor_Cells_myelin_depleted, F05570-GEX_F05608-CAR
- GSM8138401 Tumor, UPN-625, Pre-treatment, Tumor_Cells_myelin_depleted, F05570-GEX_F05630-TCR
- GSM8138402 CAR Product, UPN-626, Product, F05565-GEX_F05607-CAR
- GSM8138403 CAR Product, UPN-626, Product, F05565-GEX_F05629-TCR
- GSM8138404 Tumor, UPN-625, Post-treatment, Tumor_Cells_CD45_positive, F05917-GEX_F05921-CAR
- GSM8138405 Tumor, UPN-625, Post-treatment, Tumor_Cells_CD45_negative, F05918-GEX_F05922-CAR
- GSE308973 Localized PD-1 CAR T therapy reprograms neuroinflammation - human CSF data. 88 samples shares csf, car
- GSE296419 The critical role of the host endogenous immune compartment after intracerebroventricular CAR T cell therapy in recurrent GBM 143 samples shares car, endogenous
- GSE318420 Immunosuppressive monocytes are enriched in hepatocellular carcinoma patients with liver dysfunction in a phase II trial of combination sorafenib and nivolumab 210 samples shares car
- GSE279392 Single-cell RNA and TCR sequencing from skin, blood and cerebral spinal fluid (CSF) samples from Degos disease patients 116 samples shares csf
- GSE317520 Mitochondrial DNA Mutations Drive Tumor Heterogeneity in Papillary Thyroid Carcinoma 92 samples shares car
- GSE235863 T cell populations correlate with response and resistance to anti-PD-1 plus lenvatinib combination therapy in hepatocellular carcinoma 69 samples shares car
- GSE286518 Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease 42 samples shares csf
- GSE272348 Late-stage tertiary lymphoid structures in hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade 31 samples shares car
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.